查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012048

糖尿病護理設備市場：2026年至2032年全球市場預測（按設備類型、技術、給藥方法、胰島素類型、分銷管道和最終用戶分類）

Diabetes Care Devices Market by Device Type, Technology, Delivery Mode, Insulin Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，糖尿病護理設備市場價值將達到 321.8 億美元，到 2026 年將成長至 363.4 億美元，到 2032 年將達到 777.2 億美元，複合年成長率為 13.42%。

主要市場統計數據
基準年 2025 321.8億美元
預計年份：2026年 363.4億美元
預測年份 2032 777.2億美元
複合年成長率 (%) 13.42%

糖尿病護理設備市場正經歷一場變革，其驅動力包括技術的快速成熟、護理模式的轉變以及患者和保險公司日益成長的期望。感測器精度、演算法控制和無線互通性的進步，重新定義了臨床醫生和糖尿病患者對設備的需求：持續的洞察、可操作的自動化以及與日常生活和臨床工作流程的無縫整合。同時，醫療保健系統越來越關注療效和價值，推動報銷路徑和採購決策優先考慮那些已被證實能夠改善血糖控制、減少併發症並降低整體醫療成本的設備。

在這些因素的共同作用下，製造商、技術合作夥伴和醫療服務提供者正在不斷完善其產品藍圖和商業策略。創新日益以患者為中心，重點在於易用性、減輕設備負擔和數據透明度。監管機構正在修訂其指導方針，以應對軟體主導治療方法和複雜產品，而供應鏈和製造方面的考量在商業性可行性方面發揮著至關重要的作用。這些發展預示著一個快速變革的時代即將到來，在這個時代，臨床療效、互聯互通性、監管靈活性和營運韌性將決定市場領導地位。

閉合迴路自動化、即時連接、智慧給藥方案和分散式護理模式如何改變糖尿病設備的開發和商業化。

在糖尿病照護設備領域，變革正在發生，重塑治療模式和商業策略。首先，結合持續感測和自動胰島素輸注的閉合迴路系統已從小眾研究原型發展成為商業性可行性的治療方案。因此，臨床路徑正在調整，納入演算法決策支援和遠端監測，護理模式也從間歇性就診轉向持續性照顧。

評估美國 2025 年的關稅措施及其對糖尿病醫療設備籌資策略、價格趨勢和製造地的連鎖影響。

美國將於2025年開始徵收關稅，這將對糖尿病護理設備的採購、定價策略以及整個供應鏈產生一系列累積影響。依賴跨境零件採購的製造商正面臨原物料成本飆升的困境，被迫即時調整籌資策略和供應商合約。為應對這項挑戰，一些企業加快了近岸外包的步伐，或實現了供應商多元化，以降低風險；而另一些企業則尋求透過合約條款來分擔或承擔關稅相關成本。在企業努力控制成本與維持服務水準之間尋求平衡的過程中，這些營運調整正在影響生產前置作業時間和庫存管理。

詳細的細分分析揭示了設備類型、感測和給藥技術、胰島素配方、分銷管道和最終用戶環境如何相互交織，從而塑造產品策略。

對市場細分的詳細分析揭示了不同設備系列、技術、給藥方式、胰島素製劑、分銷管道和終端用戶在成長方向和臨床價值方面的差異。從設備類型來看，市場構成涵蓋了從全封閉回路型和混合封閉回路型架構的全自動人工胰腺系統到包括連續血糖監測、瞬時血糖監測和血糖自我監測在內的血糖監測設備。注射輔助器具包括輸液器、筆針和注射器針頭，而胰島素筆則包括預填充填充一次性胰島素筆、可重複使用胰島素筆以及日益精密的智慧胰島素筆。胰島素幫浦進一步分為貼片幫浦和管式泵，兩者在配戴舒適度和儲液容量方面各有優劣。

對美洲、歐洲、中東和非洲以及亞太地區影響商業性成功的法規結構、還款促進因素和實施路徑進行區域比較分析。

區域趨勢正顯著影響著美洲、歐洲、中東和非洲以及亞太地區的監管路徑、報銷框架和產品推廣速度。在美洲，對支付方模式和基於價值的合約的高度重視要求製造商證明其產品具有治療效果和成本效益。這有利於那些能夠顯著降低急性事件和住院率的醫療設備，從而加速在擁有完善醫保覆蓋的患者群體中推廣互聯系統。同時，在歐洲、中東和非洲，管理體制和採購慣例日益多樣化。一些歐洲市場實行集中核准和國家層級的價格談判，而其他地區則存在准入不均的情況，這就要求在市場准入和循證策略方面採取差異化策略。

主要糖尿病醫療設備製造商的策略行動和競爭措施主要集中在平台整合、夥伴關係、證據生成和供應彈性方面。

糖尿病醫療設備領域的主要企業正將產品創新與生態系統夥伴關係和資本紀律相結合。關鍵策略措施包括：拓展平台，提供集感測、給藥和分析於一體的端到端解決方案；與胰島素生產商和數位醫療公司建立垂直合作關係；以及選擇性地投資於生產能力，以更好地保障供應連續性。一些企業正專注於發展軟體即服務 (SaaS) 模式，將分析和護理管理功能以及設備硬體本身實現盈利；而另一些企業則專注於透過小型化、提升佩戴舒適度和增強用戶體驗來實現硬體差異化。

醫療器材製造商面臨的策略挑戰是如何協調臨床價值、供應彈性、互通性和區域商業化方法，以實現永續成長。

在技​​術快速發展和支付方審查日益嚴格的環境下，行業領導企業應採取一系列切實可行的舉措，以確保永續的競爭優勢。首先，他們應使產品設計與支付方和醫療服務提供者重視的可衡量結果保持一致，並將循證實踐融入產品生命週期，以縮短報銷時間並優先考慮端到端的臨床價值。其次，他們應透過結合近岸製造和多層供應商契約，實現價值鏈多元化，從而降低關稅風險和零件供應中斷的影響。第三，他們應投資於互通性和開放標準，使醫療設備能夠整合到電子健康記錄和社區健康管理平台中，從而促進醫療系統採用這些標準。

我們採用嚴格的混合方法，結合監管、臨床和商業性證據以及專家訪談和情境分析，來檢驗我們的見解和建議的有效性。

本報告採用混合方法整合證據，結合全面的二手資料研究、一手質性研究和檢驗，以確保其可靠性。二手資料來源包括監管文件、同行評審的臨床文獻、企業技術揭露和政策公告，這些資料提供了事實背景和監管環境。一手研究包括對臨床意見領袖、採購專家和高級商業主管進行結構化訪談，以及與保險公司和糖尿病護理協調員進行有針對性的討論，以檢驗商業性和報銷趨勢。

整合策略挑戰，凸顯向綜合、主導糖尿病護理解決方案的過渡以及規模化所需的營運韌性。

總之，在自動化、互聯互通和護理模式轉移轉變的驅動下，糖尿病護理設備產業正從漸進式改善轉向系統級轉型。相關人員，將更有利於把握新的機會。同時，透過多元化的供應鏈、區域製造夥伴關係和積極的關稅措施來體現的業務永續營運韌性，已不再是後勤部門的挑戰，而是保持競爭力的必要條件。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 糖尿病護理設備市場：依設備類型分類

  • 人工胰臟系統
    • 完全封閉回路型
    • 混合閉合迴路
  • 血糖監測設備
    • 持續血糖監測
    • 瞬時血糖監測
    • 自測血糖
  • 注射輔助器具
    • 注射套裝
    • 筆針
    • 針頭
  • 胰島素筆
    • 預填充一次性筆
    • 可重複使用的筆
    • 智慧筆
  • 胰島素幫浦
    • 貼片幫浦
    • 管式幫浦
  • 胰島素注射器

第9章 糖尿病護理設備市場：依技術分類

  • 持續血糖監測
    • 即時連續血糖監測
    • 回顧性連續血糖監測
  • 瞬時血糖監測
  • 自測血糖
    • 血糖儀
    • 《採血針》
    • 測量條

第10章 糖尿病照護設備市場：依給藥方式分類

  • 持續管理
  • 間歇性給藥

第11章 糖尿病照護設備市場：依胰島素類型分類

  • 中間類型
  • 長效型
    • 德特米爾
    • 格拉金
  • 超速效型
    • Aspart
    • Glulisine
    • Lispro
  • 快速起效
  • 超長效

第12章 糖尿病護理設備市場：依通路分類

  • 線上管道
  • 離線
    • 零售藥房
    • 醫院藥房

第13章 糖尿病護理設備市場：依最終用戶分類

  • 診斷中心
  • 居家照護
  • 醫院和診所
    • 糖尿病專科診所
    • 一般診所

第14章 糖尿病照護設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 糖尿病照護設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 糖尿病照護設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國：糖尿病照護設備市場

第18章 中國：糖尿病護理設備市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acon Laboratories Inc.
  • ARKray Inc.
  • Ascensia Diabetes Care Holdings AG
  • B. Braun Melsungen AG
  • Becton Dickinson and Company BD
  • Bionime Corporation
  • Dexcom Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • LifeScan Inc.
  • Medtronic plc
  • Menarini Diagnostics
  • MicroTech Medical Inc.
  • Nipro Corporation
  • Novo Nordisk A/S
  • Sanofi
  • Senseonics Holdings Inc.
  • Sinocare
  • Tandem Diabetes Care Inc.
  • Terumo Corporation
  • Trividia Health
  • Valeritas Holdings Inc.
  • Ypsomed Holding AG
Product Code: MRR-43539E5D2EA5

The Diabetes Care Devices Market was valued at USD 32.18 billion in 2025 and is projected to grow to USD 36.34 billion in 2026, with a CAGR of 13.42%, reaching USD 77.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 32.18 billion
Estimated Year [2026] USD 36.34 billion
Forecast Year [2032] USD 77.72 billion
CAGR (%) 13.42%

The diabetes care devices landscape is at a pivotal moment, driven by rapid technological maturation, shifting care delivery models, and intensifying expectations from patients and payers alike. Advances in sensor accuracy, algorithmic control, and wireless interoperability have recalibrated what clinicians and people living with diabetes expect from devices: continuous insights, actionable automation, and seamless integration into daily life and clinical workflows. At the same time, healthcare systems are emphasizing outcomes and value, prompting reimbursement pathways and procurement decisions to prioritize devices that demonstrably improve glycemic control, reduce complications, and lower total cost of care.

As these forces converge, manufacturers, technology partners, and healthcare providers are refining product roadmaps and commercial strategies. Innovation is increasingly patient-centric, focusing on ease of use, reduced device burden, and data transparency. Regulatory authorities are evolving guidance to accommodate software driven therapeutics and combination products, while supply chain and manufacturing considerations now play an outsized role in commercial viability. Taken together, these dynamics set the stage for a period of accelerated disruption where clinical efficacy, connectivity, regulatory agility, and operational resilience will determine market leadership.

How closed-loop automation, real-time connectivity, smart delivery options, and decentralized care models are reshaping diabetes device development and commercialization

The landscape of diabetes care devices has undergone transformative shifts that are redefining therapeutic paradigms and commercial playbooks. First, closed-loop systems that combine continuous sensing with automated insulin delivery have transitioned from niche research prototypes to commercially viable therapeutic options. As a result, clinical pathways are adapting to incorporate algorithmic decision support and remote monitoring, moving care from episodic encounters to continuous care relationships.

Concurrently, the proliferation of connected devices and cloud platforms has created richer longitudinal datasets that enable more personalized therapy adjustments and population-level analytics. This data availability is catalyzing partnerships between device manufacturers, software developers, and payers, fostering an ecosystem where interoperability and secure data exchange are commercial differentiators. In parallel, the rise of smart pens and advanced injection aids has broadened the options for insulin delivery, offering alternatives that can bridge the gap between lifestyle convenience and clinical efficacy. Finally, the industry is witnessing a shift toward decentralization of care: telehealth, home diagnostics, and remote titration are reducing the reliance on centralized clinics, and in doing so, reshaping distribution strategies, educational outreach, and customer support models.

Assessment of the 2025 United States tariff measures and their cascading effects on sourcing strategies, pricing dynamics, and manufacturing footprints across diabetes devices

The imposition of tariffs in the United States during 2025 has introduced a set of cumulative effects that ripple across procurement, pricing strategies, and supply chains for diabetes care devices. Manufacturers that rely on cross-border component sourcing have encountered escalated input costs, prompting immediate reassessment of sourcing strategies and supplier contracts. In response, some organizations accelerated nearshoring initiatives or diversified supplier bases to mitigate exposure, while others sought contractual clauses to share or absorb tariff related costs. These operational adjustments have implications for production lead times and inventory management as firms balance cost containment with service level commitments.

From a commercial perspective, tariffs have created pressure on device pricing and reimbursement negotiations. Payers and purchasing groups have become more vigilant about unit costs and lifecycle expenditures, which in turn influences formulary decisions and tender outcomes for hospitals and clinics. Some manufacturers opted to absorb tariff impacts temporarily to preserve market access, while others introduced price adjustments tied to specific product lines. At the same time, the tariff environment has incentivized investment in domestic manufacturing capabilities and strategic partnerships with local contract manufacturers, reflecting a longer-term pivot to reduce trade risk. Ultimately, the tariff episode accelerated structural shifts in sourcing, manufacturing footprint decisions, and commercial terms that will influence competitive dynamics beyond the immediate fiscal cycle.

Deep segmentation analysis revealing how device type, sensing and delivery technologies, insulin formulations, channels, and end user settings intersect to shape product strategies

A nuanced view of segmentation reveals divergent growth vectors and differentiated clinical value across device families, technologies, delivery modes, insulin formulations, channels, and end users. When examined by device type, the market composition ranges from fully automated artificial pancreas systems comprising full closed loop and hybrid closed loop architectures to glucose monitoring devices that cover continuous glucose monitoring, flash glucose monitoring, and self-monitoring blood glucose. The injection aids spectrum includes infusion sets, pen needles, and syringe needles, while insulin pens span prefilled disposable pens, reusable pens, and increasingly sophisticated smart pens. Insulin pumps are further categorized into patch pumps and tubed pumps, each offering distinct tradeoffs in wearability and reservoir capacity.

Looking through a technology lens, continuous glucose monitoring itself bifurcates into real-time continuous glucose monitoring and retrospective continuous glucose monitoring, and remains distinct from flash glucose monitoring and self-monitoring blood glucose approaches; the latter includes glucose meters, lancets, and test strips. Delivery mode segmentation divides offerings into continuous delivery and intermittent delivery, which align to different clinical profiles and patient preferences. Insulin types span intermediate acting through ultra long acting formulations, with commonly used long acting analogues such as detemir and glargine and rapid acting analogues including aspart, glulisine, and lispro shaping device compatibility and dosing algorithms. Distribution channel dynamics encompass direct sales, hospital pharmacies, online channels, and retail pharmacies, with retail channels further split between chain and independent pharmacies. Finally, end user segmentation covers diagnostic centers, home care settings, and hospitals and clinics, where the latter includes specialized diabetes clinics as well as general clinics.

Taken together, these segmentation layers intersect to inform product design priorities, clinical positioning, and go-to-market approaches. For example, smart pens and continuous technologies align strongly with home care adoption and online distribution, while hybrid and full closed loop systems require integrated support from hospitals, diabetes clinics, and specialized diagnostic services during early adoption phases. Manufacturers should therefore map technology choices to distribution and end user pathways to optimize clinical impact and commercial uptake.

Comparative regional intelligence on regulatory frameworks, reimbursement drivers, and adoption pathways across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine commercial success

Regional dynamics materially influence regulatory pathways, reimbursement frameworks, and adoption tempos across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, payer models and a strong emphasis on value-based contracting have pushed manufacturers to demonstrate outcomes and cost offsets. This has favored devices that enable measurable reductions in acute events and hospital utilization, and has accelerated uptake of connected systems in populations with established coverage pathways. Conversely, Europe, Middle East & Africa presents a mosaic of regulatory regimes and procurement practices; centralized approvals and national pricing negotiations in some European markets contrast with heterogeneous access in other jurisdictions, requiring differentiated market entry and evidence generation strategies.

Asia-Pacific markets exhibit diverse demand drivers, where high population density and rising prevalence create scale opportunities, while variable reimbursement and income levels necessitate tiered product offerings and channel innovation. In several markets, local manufacturing partnerships and licensing arrangements have been critical to navigating import duties and securing preferred provider status. Across regions, technology adoption curves differ: while some countries rapidly embrace continuous monitoring and closed-loop approaches, others prioritize cost-effective intermittent delivery solutions and robust supply chain resilience. Manufacturers should therefore calibrate clinical evidence dossiers, pricing approaches, and partnership models in accordance with regional payer expectations and regulatory realities to maximize adoption and reimbursement success.

Strategic behaviors and competitive moves among leading diabetes device manufacturers focused on platform integration, partnerships, evidence generation, and supply resilience

Leading companies in the diabetes devices space are aligning product innovation with ecosystem partnerships and capital discipline. Key strategic behaviors include platform expansion to deliver end-to-end solutions that combine sensing, delivery, and analytics; vertical partnerships with insulin manufacturers and digital health firms; and selective investments in manufacturing capabilities to enhance control over supply continuity. Some organizations emphasize software as a service models, monetizing analytics and care management features alongside device hardware, while others double down on hardware differentiation through miniaturization, improved wearability, and enhanced user experience.

Competitive dynamics are also shaped by M&A, licensing, and co-development agreements that accelerate time to market for complex combination products. Companies that succeed tend to integrate clinical evidence generation into commercialization plans early, aligning randomized and real-world evidence to payer decision needs. Additionally, leaders invest in customer education, professional training, and post-market surveillance to reinforce clinical trust and reduce device attrition. Finally, a growing number of firms are committing to sustainability in manufacturing and packaging as a reputational and cost consideration, recognizing that procurement teams increasingly factor environmental impact into purchasing decisions.

Actionable strategic imperatives for device manufacturers to align clinical value, supply resilience, interoperability, and regional commercialization approaches for sustained growth

Industry leaders should pursue a set of pragmatic actions to secure durable advantage in a landscape defined by technological acceleration and payer scrutiny. First, prioritize end-to-end clinical value by aligning product design with measurable outcomes that matter to payers and providers, and embed evidence generation in product lifecycles to shorten reimbursement timelines. Second, diversify supply chains by combining nearshore manufacturing options with multi-tier supplier agreements to mitigate tariff exposure and component disruptions. Third, invest in interoperability and open standards to ensure devices can integrate into electronic health records and population health platforms, thereby increasing adoption by health systems.

Fourth, develop tiered commercial offerings that address distinct regional affordability profiles, pairing premium, fully integrated systems with simplified, cost-effective alternatives for resource constrained markets. Fifth, cultivate strategic partnerships with insulin producers, digital therapeutics firms, and telehealth providers to create bundled solutions that align incentives across stakeholders. Sixth, accelerate post-market programs that support clinician training and patient onboarding, reducing friction in adoption and improving retention. Together, these actions will enable manufacturers to navigate regulatory complexities, respond to evolving clinical expectations, and capture long-term share in an increasingly outcomes-oriented market.

Rigorous mixed methods research combining regulatory, clinical, and commercial evidence with expert interviews and scenario analysis to validate insights and recommendations

This report synthesizes evidence using a mixed-methods approach that combines comprehensive secondary research with primary qualitative inquiry and triangulation to ensure robustness. Secondary inputs include regulatory filings, peer-reviewed clinical literature, company technical disclosures, and policy announcements that establish the factual backdrop and regulatory context. Primary research incorporated structured interviews with clinical opinion leaders, procurement specialists, and senior commercial executives, along with targeted discussions with payers and diabetes care coordinators to validate commercial and reimbursement dynamics.

Analytical processes included cross-validation of qualitative insights against published clinical outcomes and regulatory guidance, scenario analysis to stress test the implications of tariffs and supply disruptions, and thematic coding of interview outputs to surface recurring adoption barriers and enablers. Quality assurance steps encompassed independent review by subject matter experts and reconciliation of divergent viewpoints to create balanced conclusions. Ethical research conduct and data privacy protocols were maintained throughout, ensuring that proprietary commercial information was handled under confidentiality and that synthesized findings reflect consensus where possible rather than single-source assertions.

Synthesis of strategic imperatives underscoring the transition to integrated, evidence-driven diabetes care solutions and the operational resilience required for scale

In conclusion, the diabetes care devices sector is transitioning from incremental improvement to systems-level transformation, driven by automation, connectivity, and shifting care paradigms. Stakeholders who move beyond product centric thinking to embrace integrated solutions that deliver measurable clinical and economic value will be best positioned to capture emerging opportunities. At the same time, operational resilience-manifested through diversified supply chains, regional manufacturing partnerships, and proactive tariff mitigation-has become a competitive necessity rather than a back-office concern.

Looking ahead, success will hinge on the ability to translate rich device-generated data into actionable clinical workflows, to secure payer alignment through strong evidence packages, and to offer flexible commercial models adapted to regional contexts. For manufacturers, investors, and healthcare systems alike, the mandate is clear: pursue innovations that make diabetes care simpler, safer, and more accessible, while building the commercial and operational muscle to deliver those innovations at scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Care Devices Market, by Device Type

  • 8.1. Artificial Pancreas Systems
    • 8.1.1. Full Closed Loop
    • 8.1.2. Hybrid Closed Loop
  • 8.2. Glucose Monitoring Devices
    • 8.2.1. Continuous Glucose Monitoring
    • 8.2.2. Flash Glucose Monitoring
    • 8.2.3. Self Monitoring Blood Glucose
  • 8.3. Injection Aids
    • 8.3.1. Infusion Sets
    • 8.3.2. Pen Needles
    • 8.3.3. Syringe Needles
  • 8.4. Insulin Pens
    • 8.4.1. Prefilled Disposable Pens
    • 8.4.2. Reusable Pens
    • 8.4.3. Smart Pens
  • 8.5. Insulin Pumps
    • 8.5.1. Patch Pumps
    • 8.5.2. Tubed Pumps
  • 8.6. Insulin Syringes

9. Diabetes Care Devices Market, by Technology

  • 9.1. Continuous Glucose Monitoring
    • 9.1.1. Real Time Continuous Glucose Monitoring
    • 9.1.2. Retrospective Continuous Glucose Monitoring
  • 9.2. Flash Glucose Monitoring
  • 9.3. Self Monitoring Blood Glucose
    • 9.3.1. Glucose Meters
    • 9.3.2. Lancets
    • 9.3.3. Test Strips

10. Diabetes Care Devices Market, by Delivery Mode

  • 10.1. Continuous Delivery
  • 10.2. Intermittent Delivery

11. Diabetes Care Devices Market, by Insulin Type

  • 11.1. Intermediate Acting
  • 11.2. Long Acting
    • 11.2.1. Detemir
    • 11.2.2. Glargine
  • 11.3. Rapid Acting
    • 11.3.1. Aspart
    • 11.3.2. Glulisine
    • 11.3.3. Lispro
  • 11.4. Short Acting
  • 11.5. Ultra Long Acting

12. Diabetes Care Devices Market, by Distribution Channel

  • 12.1. Online Channels
  • 12.2. Offline
    • 12.2.1. Retail Pharmacies
    • 12.2.2. Hospital Pharmacies

13. Diabetes Care Devices Market, by End User

  • 13.1. Diagnostic Centers
  • 13.2. Home Care
  • 13.3. Hospitals And Clinics
    • 13.3.1. Diabetes Clinics
    • 13.3.2. General Clinics

14. Diabetes Care Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Diabetes Care Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Diabetes Care Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Diabetes Care Devices Market

18. China Diabetes Care Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Acon Laboratories Inc.
  • 19.7. ARKray Inc.
  • 19.8. Ascensia Diabetes Care Holdings AG
  • 19.9. B. Braun Melsungen AG
  • 19.10. Becton Dickinson and Company BD
  • 19.11. Bionime Corporation
  • 19.12. Dexcom Inc.
  • 19.13. Eli Lilly and Company
  • 19.14. F. Hoffmann-La Roche Ltd.
  • 19.15. Insulet Corporation
  • 19.16. LifeScan Inc.
  • 19.17. Medtronic plc
  • 19.18. Menarini Diagnostics
  • 19.19. MicroTech Medical Inc.
  • 19.20. Nipro Corporation
  • 19.21. Novo Nordisk A/S
  • 19.22. Sanofi
  • 19.23. Senseonics Holdings Inc.
  • 19.24. Sinocare
  • 19.25. Tandem Diabetes Care Inc.
  • 19.26. Terumo Corporation
  • 19.27. Trividia Health
  • 19.28. Valeritas Holdings Inc.
  • 19.29. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES CARE DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES CARE DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES CARE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FULL CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INFUSION SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PEN NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SYRINGE NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PREFILLED DISPOSABLE PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REUSABLE PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SMART PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY PATCH PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TUBED PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REAL TIME CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETROSPECTIVE CONTINUOUS GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY FLASH GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE METERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LANCETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMITTENT DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY INTERMEDIATE ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ULTRA LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIABETES CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIABETES CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY DIABETES CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY ARTIFICIAL PANCREAS SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY GLUCOSE MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INJECTION AIDS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PENS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INSULIN PUMPS, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY SELF MONITORING BLOOD GLUCOSE, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY INSULIN TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY LONG ACTING, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY RAPID ACTING, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC DIABETES CARE DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. GLOBAL DIABETES CARE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN DIABETES CARE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN DIABETES CARE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD